Combining bioreductive drugs and radiation for the treatment of solid tumors*,**
Section snippets
Early concepts in the development of bioreductive drugs
The idea of bioreductive drug activation and the selective killing of hypoxic cells developed along 2 complimentary pathways. The first of these arose from observations made by Sutherland8 who noted that the hypoxic cell radiosensitizer, metronidazole, appeared to selectively kill the central hypoxic cells in multicellular spheroids. The second approach came from the recognition by Kennedy et al9 and Sartorelli10 that the presence of hypoxia in tumors created an environment conducive to
Bioreductive drugs used with radiation
The observations that hypoxic cell radiosensitizers could also function as hypoxic cell cytotoxins led to a more detailed evaluation of what contribution cytotoxicity could make to the outcome of radiosensitization experiments carried out in vivo. Conventionally, radiosensitizers such as metronidazole, misonidazole, etanidazole, and nimorazole are given to experimental mice before radiation because for sensitisation to occur drugs only need to be present in the hypoxic tumour cells at the
Future directions
Denny and colleagues3 first articulated the trigger/effecter concept in bioreductive drug development. Examples are given in Figures 3 and 4 in which the bioreductive prodrugs are putatively inactive until subjected to reductive metabolism under hypoxic conditions. Addition of a single electron will cause structural
Conclusions
The development of bioreductive drugs might be regarded as a mature science waiting for definitive, repeatable, clinical evidence that their use in combination with radiotherapy alone or chemo/radiotherapy will be of therapeutic benefit. However, the indicators are promising. There is firstly the positive interaction of TPZ combined with cisplatin in the treatment of non–small-cell lung cancer. Secondly, there are the positive clinical trials combining radiotherapy with MMC in the treatment of
References (83)
- et al.
Bioreductive therapies: An overview of drugs and their mechanisms of action
Int J Radiat Oncol Biol Phys
(1998) - et al.
Hypoxia as a target for combined modality treatments
Eur J Cancer
(2002) - et al.
The hypoxic tumor cell: A target for selective cancer chemotherapy
Biochem Pharmacol
(1980) - et al.
Nitroimidazole bioreductive metabolism: Quantitation and characterisation of mouse tissue benzonidazole nitroreductases in vivo and in vitro
Biochem Pharmacol
(1987) - et al.
Enzymology of the reductive bioactivation of SR 4233: A novel benzotriazine di-N-oxide hypoxic cell cytotoxin
Biochem Pharmacol
(1990) - et al.
The importance of P450 reductase for determining the sensitivity of human tumour cells to the indolequinone E09 and related analogues lacking functionality in the C-2 and C-3 positions
Biochem Pharmacol
(2000) - et al.
Expression of the bacterial nitroreductases enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954
Eur J Cancer
(1995) - et al.
Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131
Biochem Pharmacol
(1987) - et al.
Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice
Toxicol Appl Pharmacol
(2000) - et al.
Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233
Radiother Oncol
(1988)
Pre-and post-irradiation radiosensitization by SR 4233
Int J Rad Oncol Biol Phys
The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay
Int J Radiat Oncol Biol Phys
Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen
Int J Radiat Oncol Biol Phys
Sensitizers and radiation dose fractionation: Results and interpretations
Int J Radiat Oncol Biol Phys
Fractionation increases the antitumour effect of adding a hypoxic cytotoxin to irradiation
Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer
Int J Radiat Oncol Biol Phys
Exploring the mechanistic aspects of mitomycing antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH: Cytochrome C (P450) reductase and DT-diaphorase
Adv Enzyme Regul
Metabolism and reactions of quinoid anticancer agents
Pharmacol Ther
Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia
Eur J Cancer
Bioreductive drugs for cancer therapy: The search for tumor specificity
Int J Radiat Oncol Biol Phys
Development, pharmacology, role of DT-diaphorase and prospects of the indolequinone EO9
Gene Pharmacol
A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC early clinical studies group (ECSG)
Ann Oncol
Bioreductively-activated prodrugs for targeting hypoxic tissues: Elimination of Aspirin from 2-nitroimidazole derivatives
Bio Med Chem Lett
Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy
Neoplasia
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
Radiother Oncol
Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue
Bioorg Med Chem
The experimental development of bioreductive drugs and their role in cancer therapy
Cancer Met Rev
Hypoxia-specific cytotoxins in cancer therapy
Semin Radiat Oncol
Recent developments in the design of bioreductive drugs
Br J Cancer
Bioreductive drugs into the next millennium
Anti-Cancer Drug Design
Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia
Curr Med Chem
Selective chemotherapy of non-cycling cells in an in vitro tumour model
Cancer Res
Therapeutic attack of hypoxic cells of solid tumours: presidential address
Cancer Res
Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells
Cancer Res
The chemistry of nitroarene and aromatic N-oxide radicals
Split dose cytotoxic experiments with misonidazole
Br J Cancer
Sulphydryls, ascorbate and oxygen as modifiers of the toxicity and metabolism of misonidazole in vitro
Br J Cancer
Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin
Cancer Res
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors
J Clin Oncol
Overexpression of human NADPH: Cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069
Br J Cancer
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)
Br J Cancer
Cited by (0)
- *
Supported by the Medical Research Council Grant Number G9520193.
- **
Address reprint requests to Ian J. Stratford, PhD, School of Pharmacy and Pharmaceutical Sciences, University of Manchester Coupland III Building, Oxford Road, Manchester M13 9PL, UK.